Latest news with #biomarker
Yahoo
5 days ago
- Business
- Yahoo
Year-End Report 2024/2025
UPPSALA, SE / / June 18, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Positive development in the USA continues SEK t Q424/25 Q423/24 May-April 24/25 May-April 23/24 Net sales 2,332 1,899 8,619 7,290 Operating profit (loss) -20,341 -41,490 -85,839 -126,845 Profit (loss) for the period -20,766 -39,532 -87,624 -124,823 Earnings per share after dilution -0.21 -0.47 -0.95 -2.14 Number of shares at the end of the period 97,786,384 84,055,560 92,569,248 84,055,560 Cash and cash equivalents at the end of the period 24,415 79,407 24,415 79,407 Cash flow from operating activities -17,826 -25,251 -85,367 -114,575 Average number of employees 26 35 27 37 Biovica in brief - Treatment decisions with greater certainty Biovica's vision is: "Improved care for cancer patients." Biovica develops and commercializes the blood-based biomarker assay, DiviTum TKa, which enables early-stage evaluation of treatment effectiveness. The initial focus is on breast cancer. The initial focus area is metastatic breast cancer, however study results since 2024 show that DiviTum TKa can also serve as both a predictive and prognostic tool in the adjuvant treatment of early-stage breast cancer. DiviTum TKa has obtained FDA 510(k) clearance in the USA and has CE marking in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Webcast:When: 18 June 2025, 3 PM to 4 PM CETWhere: register via: language: in English Significant events during the fourth quarter Biovica signed an agreement with Eurobio Scientific covering 60% of the European market Biovica has secured a new work order worth SEK 2.5 million for TKa testing services in the Pharma Services part of the business Biovica and Outcomes4Me have embarked on a new collaboration to empower patients with metastatic breast cancer to better understand how well their treatment is working DiviTum TKa data in combination with inflammation proteins presented at the AACR meeting enhance precision to predict efficacy of immunotherapy Significant events during the third quarter DiviTum TKa results presented at ASCO, the world's largest cancer conference Biovica signed new drug development agreement Extraordinary general meeting of Biovica International AB Biovica carried out a directed new issue of units for approximately SEK 16.4 million Biovica signed an agreement with US Biotech company in clinical phase Biovica secured a significant order for TKa testing services Biovica published the outcome of exercise of warrants from series TO3B. Biovica signed a master service agreement (MSA) with UK biotech company NewDivitum TKa data that significantly increases the market potential presented at SABCS Biovica signed an agreement with US healthcare and insurance giant Biovica's CLIA lab obtained a permit from the state of New York, which opens up the entire US market Biovica secured yet another significant order for TKa testing services Significant events after the end of the period Biovica is now collaborating with Tempus to expand the commercial reach of DiviTum TKa Biovica signed a significant Master Service Agreement (MSA) and first work under that agreement for SEK 4 million New data on DiviTum TKa use in three areas of cancer presented at ASCO Biovica secured three new assignments worth SEK 2.5 million in the Pharma Services part of the business Biovica announced financial targets subsequent to important partnership and commercial success Biovica resolved on a fully guaranteed rights issue of approximately SEK 80 million at SEK 0.63 per share Notice issued of extraordinary general meeting of Biovica International AB Biovica signed an agreement with its fifth Tier 1 biopharma company in the USA CEO's commentsImportant steps were made during the 2024/2025 financial year to establish DiviTum TKa as a standard approach to treatment monitoring in breast cancer. Strong clinical evidence, commercial success and new strategic partnerships have played a key role in solidifying our position in the US and European to the previous quarter, our sales in the USA increased by more than 25% in the fourth quarter and the positive trend has extended into the new fiscal year, following the recent close of our books. We have continued generating new clinical evidence for DiviTum TKa. The results from three cancer studies were presented at the 2025 ASCO Annual Meeting, which is the largest oncology conference in the world. The most impactful results, however, were those presented at the San Antonio Breast Cancer Symposium (SABCS) in December, where seven breast cancer studies - including two focused on early-stage disease - were shared. It opens up a new, very large market for us, with estimated market potential of up to USD 3 billion. There is a significant need within the healthcare industry to optimize and streamline the use of costly treatments - such as CDK4/6 inhibitors. This is where DiviTum TKa makes a real difference - providing evidence-based, cost-effective decision support. Further confirmation came in the form of a new agreement with a leading US healthcare and insurance giant with more than 10 million policyholders and annual revenue in excess of USD 100 billion. This organization - which serves as both a healthcare provider and health insurer - has observed that policyholders are at times prescribed costly treatments that are not always effective. The use of DiviTum TKa can enhance patient outcomes - while dramatically lowering costs for the organization. The agreement makes it possible to establish DiviTum TKa as one of their standard routines for breast cancer treatment. In May 2025, we also began a collaboration with the US-based diagnostics company Tempus AI, which will offer DiviTum TKa nationwide through its network of hundreds of sales representatives in the oncology field. Tempus AI has an impressive track record, with annual revenue growth exceeding 30%. Biovica's CLIA-certified laboratory will serve as a reference lab to Tempus AI, which will enable them to include DiviTum TKa in their collection of precision medicine solutions currently offered to more than 6,500 oncologists. Within our Pharma Services business, we continued to strengthen our relationships with the pharmaceutical industry throughout the year. Subsequent to the end of the period, we signed two new MSAs with Tier 1 (annual revenue exceeding USD 10 billion) pharmaceutical companies. An initial order of approximately SEK 5 million has already been received, with call-offs expected to take place over the next 2 to 3 years. This means that we now have 18 MSAs in place, including 5 with Tier 1 companies, representing a contract volume of approximately SEK 25 million in revenue to be recognized over the next 2 to 3 years as the services are delivered. This will be a key factor in achieving the financial targets that we have announced and an important step towards more comprehensive collaborations that could lead to new, customer-financed Companion Diagnostic (CDx) products. An additional key milestone this year was our new collaboration with Eurobio Scientific - a leading in vitro diagnostics company - which expands our commercial reach across Europe. It opens the door to eight key European markets, which together account for 60% of our priority EU markets. The combination of Eurobio's extensive hospital and laboratory network with our technology lays a strong foundation for increased test adoption across Europe. We are entering the new fiscal year with renewed confidence and increased market penetration - driven in part by the recent approval for our CLIA laboratory to offer DiviTum TKa to residents of New York State, as well as the growing interest we are seeing from both commercial partners and the clinical community. Our robust network of partners and growing presence in the clinical space position us well for continued growth, which is also reflected in the financial targets that we recently announced. The goal is to increase sales to SEK 50 million during the 2025/2026 fiscal year, derived primarily from the USA and Pharma Services. At the beginning of the financial year, we completed a targeted new share issue of SEK 16.4 million to support the continued commercialization and development of our operations. Participation came from both existing shareholders and new institutional investors. Subsequent to the end of the period there is also a rights issue underway and we are hoping for a high level of participation. Our assessment is that the guaranteed amount of SEK 80 million, based on the current business plan and in line with our previously communicated financial target, will sufficiently cover our needs until the point when the company is cash flow positive around the turn of the year 2026/2027. I would like to sincerely thank our employees, investors, clinical partners and everyone else who has contributed to our success during the year. Together, we will take the next steps toward improving treatment outcomes and quality of life for cancer patients throughout the world. Anders Rylander, CEO Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-18 08:00 CEST. Attachments Q4 2024 2025 Biovica Kommuniké 2025 04 30 Eng Final For Publikation SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio
Medical News Today
11-06-2025
- Health
- Medical News Today
Aging: Healthy habits could offset stroke, dementia, depression risk
New research finds certain diseases may be more common in people with a biomarker of aging but not in those with healthy lifestyles. Ivan Gener/Stocksy Age can increase a person's risk for several health conditions, including stroke, dementia, and late-life depression. A new study has identified an aging biomarker that is more common in people who develop stroke, dementia, and depression as they age. Researchers found that study participants who followed a healthy lifestyle appeared to offset the risks associated with this aging biomarker. 'Stroke and dementia are among the most prevalent age-related diseases, affecting millions worldwide and representing major health challenges for individuals, families, and healthcare systems,' Tamara N. Kimball, MD, a post-doctoral research fellow in the Brain Care Labs at Mass General Brigham told Medical News Today . 'With their impact expected to grow dramatically as populations age — and the number of people ages 60 and over projected to increase from 1 billion in 2020 to 1.4 billion by 2030 — developing effective prevention strategies has become urgent,' she said. Kimball is the lead author of a new study recently published in Neurology, the medical journal of the American Academy of Neurology, that has identified an aging biomarker that is more common in people who develop stroke, dementia, and depression as they age. However, researchers found that following a healthy lifestyle offsets the risk of the diseases associated with this aging biomarker. For this study, researchers analyzed medical records for more than 356,000 adults with a median age of 56 living in the U.K. 'Imagine your shoelaces have plastic tips that protect them from fraying — telomeres work similarly for your DNA,' Kimball explained. 'Every time your cells divide, which happens constantly as your body repairs and maintains itself, these protective tips get a little shorter. As they become shorter over time, their ability to protect DNA diminishes, leading to cellular aging and an increased susceptibility risk of age-related diseases.' 'The length of telomeres in white blood cells (leukocytes) can serve as a marker of biological aging and is influenced by genetic factors, lifestyle choices, and environmental stressors,' she added. At the study's conclusion, researchers found that study participants with the shortest telomere length had 5.82 cases per 1,000 person-years (number of people in the study and amount of time each person spent in the study) of the brain diseases dementia, stroke, and late-life depression, compared to 3.92 cases for participants with the longest telomeres. 'This shows people with the shortest telomeres presented (with) these brain diseases about 1.5 times more than those with the longest telomeres, demonstrating how biological aging affects brain health,' Kimball said. Scientists also discovered that study participants with short telomeres who had brain disease risk factors such as high blood pressure and smoking were 11% more likely to develop stroke, dementia, or depression than those with long telomeres. 'Our results demonstrate that individuals with low Brain Care Score — reflecting less favorable lifestyle factors like high blood pressure and smoking — consistently showed elevated risk for stroke, dementia, and depression when they also had shorter telomeres,' Kimball said. ' This suggests a compounded risk effect where biological aging and poor lifestyle choices increase disease susceptibility,' she said. Interestingly, Kimball and her team also found that participants with short telomeres, but who had high Brain Care Scores, did not have a higher risk of developing the studied brain diseases. 'In individuals with high Brain Care Score, the impact of leukocyte telomere length on disease risk was not significant,' Kimball explained. 'This may suggest that adopting healthier lifestyles and improving modifiable risk factors can mitigate the negative effects of having shorter telomeres.' 'Research shows that approximately 45% of dementia cases and up to 85% of strokes are linked to factors we can modify — like blood pressure, diet, and exercise,' she continued. 'Understanding the biological mechanisms by which lifestyle interventions influence cellular aging processes is essential for validating prevention strategies and developing more targeted, evidence-based interventions for brain health.' 'Our findings suggest that adopting healthier lifestyles and improving modifiable risk factors might mitigate some of the negative effects of shorter telomeres, which reflect adverse lifestyle choices in addition to social and environmental determinants of health earlier in life. In short, it is never too late to start taking better care of your brain.' — Tamara N. Kimball, MD MNT had the opportunity to speak with Clifford Segil, DO, an adult neurologist in private practice in Santa Monica, CA, who is also on staff at Providence St. John's Health Center in Santa Monica, CA, about this study. 'I am excited to see this research indicating a common cause of these three pathologies to develop into a possible treatment for telomere length protection or extension which could possibly decrease the occurrence of stroke, dementia, and depression in my elderly patients.' — Clifford Segil, DO Segil said that any time a common pathology is found between disparate neurological disease states, it is exciting as this research may stimulate a novel therapy. 'I often share with my patients that an ounce of prevention is worth a pound of treatment and studies like this support my desire to help my patients with common sense practical brain health preventative strategies,' he stated. For the next steps in this research, Segil said he would like to see this research group focus on specific lifestyle traits which cause patients to be able to maintain their 'large' telomere length and therefore decrease risk of stroke, dementia, and depression to figure out what to advise my patients to do for good brain health. 'I would then want them to do the reverse and figure out which habits or lifestyle choices specifically result in 'short' telomere lengths so I could advise my patients what to avoid in life,' he added. MNT also spoke with Jasdeep S. Hundal, PsyD, ABPP-CN, director of The Center for Memory & Healthy Aging at Hackensack Meridian Jersey Shore University Medical Center, and associate professor of psychiatry and neurology at Hackensack Meridian Health School of Medicine in New Jersey, about this research who commented that findings are not entirely surprising, but do add value. 'Short leukocyte telomere length has long been viewed as a general marker of biological aging and this study seems to support this association, especially for people with unhealthy lifestyles.' — Jasdeep S. Hundal, PsyD, ABPP-CN 'This reinforces what we see clinically in that modifiable risk factors remain central, even in the context of genetic or biological vulnerability, to brain health as we age even if the findings are correlational. It is interesting to speculate that short telomeres aren't necessarily causing these brain diseases, but they are a warning sign, especially in the setting of poor lifestyle choices,' Hundal explained. 'The burden of age-related brain diseases is rapidly rising, and we still have no cure for the most serious dementias like Alzheimer's disease,' he continued. 'Most of the risk factors for these diseases are modifiable, so there is real potential for prevention or risk reduction, even in people who may already be showing signs of biological aging.' Hundal said that studies like this highlight that maintaining a healthy lifestyle is not just 'good advice,' but can have genuine brain health consequences if someone is biologically vulnerable. 'We need more research identifying which interventions actually make a difference, for whom, and how to implement them in real-world settings,' he added. 'The focus should always be on translating findings like these into concrete strategies that help patients maintain brain health and independence for as long as possible.' Cholesterol Hypertension Stroke Alzheimer's / Dementia Seniors / Aging
Zawya
03-06-2025
- Business
- Zawya
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care.' Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region."
Yahoo
23-05-2025
- Business
- Yahoo
New DiviTum(R) TKa Data to be Presented at ASCO in Three Cancer Types
UPPSALA, SE / / May 23, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest cancer meeting, the American Society of Clinical Oncology (ASCO), May 30 - June 3, 2025. ASCO is the world's largest and most influential oncology conference, bringing together approximately 31,000 oncology professionals. The new data further validates DiviTum TKa as a predictive biomarker across three cancer indications: Hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients treated with CDK4/6 inhibitors in the high-profile PEARL study BRAF V600-mutated metastatic melanoma treated with Immune Checkpoint Inhibitors (ICI) Ovarian cancer treated with platinum-based chemotherapy While the PEARL study represents a large-scale trial that addresses a key clinical decision-making challenge in MBC - whether to select newer versus established treatment combinations - the studies in melanoma and ovarian cancer are more exploratory in nature. " It is exciting that DiviTum TKa will be presented to such a large audience as a predictive biomarker for personalized treatment selection in MBC, malignant melanoma , and ovarian cancer, thereby significantly extending the number of patients who can benefit from DiviTum TKa. Equally exciting, that DiviTum TKa can also predict outcomes for patients receiving the new generation Immune Checkpoint Inhibitors for malignant melanoma," said Anders Rylander, CEO of Biovica. Thank you to the long list of partners in eight European countries, who have contributed to bringing about new knowledge. More about the Abstract Title Institution Patient Population Key Findings "Thymidine kinase activity (TKa) as independent predictor of outcome in metastatic breast cancer (MBC) patients in theGEICAM/2013-02 PEARL trial: A predictive biomarker for personalized treatment selection between Capecitabine vs ET + Palbociclib in MBC" GEICAM, Spain Treatment for HR+/HER2- metastatic breast cancer (MBC) with early (≤12 months) progression. TKa can predict for personalized treatment selection between Capecitabine vs ET + Palbociclib CT vs a CDK4/6 inhibitor influence TKa response differently, and the direction and magnitude of the TKa response can predict for benefit to a specific original PEARL study analysis showed no outcome differences between Cape vs ET + Palbo in HR+/HER2- MBC pts, however assessment of TKa before and during therapy identified which patients had the highest probability of responding. "Serum Thymidine Kinase Activity (TKa) as a Potential Biomarker in the Sequential Immunotherapy and Targeted Therapy for Metastatic BRAF V600 Mutated Melanoma (SECOMBIT) trial" 30 centers in: Austria, France Greece, Italy, Spain, Sweden, and Switzerland BRAF V600 mutatedmetastatic melanoma TKa can predict patient outcome inBRAF V600 mutated metastatic melanomaPatients with elevated TKa is an evident poor prognosis study to evaluate the role of TKa as a biomarker in a prospective clinical trial in patients with metastatic melanoma. "Thymidine kinase activity as a prognostic and predictive tool in blood samples from primary ovarian cancer patients" University of Duisburg-Essen, Germany Ovarian Cancer Baseline TKa levels in both serum and plasma significantly correlated with OS and DFS, which identifies circulating TKa as a promising prognostic marker in OC. It might further serve as a predictive marker for response to platinum-based chemotherapy. However, prospective validation of these results is needed in order to further specify the clinical value of TKa. List of abbreviationsBC Breast CancerBL Base Line - prior to treatmentBRAF V600 BRAF is a human gene responsible for producing the protein B-Raf, which is involved in signaling direct cell growth. The V600E mutation describes an amino acid substitution at position 600 in BRAF from a valine (V) to a glutamic acid (E)CDK4/6i CDK4/6 inhibitor treatmentsDFS Disease-Free SurvivalHER2 Human Epidermal Growth Factor Receptor 2HR Hormone receptorHR+ Hormone receptor-positiveMBC Metastatic Breast CancerOS Overall SurvivalPts PatientsTKa Thymidine Kinase activity Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments New DiviTum® TKa data to be presented at ASCO in three cancer types SOURCE: Biovica International View the original press release on ACCESS Newswire
Yahoo
23-05-2025
- Business
- Yahoo
New DiviTum(R) TKa Data to be Presented at ASCO in Three Cancer Types
UPPSALA, SE / / May 23, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest cancer meeting, the American Society of Clinical Oncology (ASCO), May 30 - June 3, 2025. ASCO is the world's largest and most influential oncology conference, bringing together approximately 31,000 oncology professionals. The new data further validates DiviTum TKa as a predictive biomarker across three cancer indications: Hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients treated with CDK4/6 inhibitors in the high-profile PEARL study BRAF V600-mutated metastatic melanoma treated with Immune Checkpoint Inhibitors (ICI) Ovarian cancer treated with platinum-based chemotherapy While the PEARL study represents a large-scale trial that addresses a key clinical decision-making challenge in MBC - whether to select newer versus established treatment combinations - the studies in melanoma and ovarian cancer are more exploratory in nature. " It is exciting that DiviTum TKa will be presented to such a large audience as a predictive biomarker for personalized treatment selection in MBC, malignant melanoma , and ovarian cancer, thereby significantly extending the number of patients who can benefit from DiviTum TKa. Equally exciting, that DiviTum TKa can also predict outcomes for patients receiving the new generation Immune Checkpoint Inhibitors for malignant melanoma," said Anders Rylander, CEO of Biovica. Thank you to the long list of partners in eight European countries, who have contributed to bringing about new knowledge. More about the Abstract Title Institution Patient Population Key Findings "Thymidine kinase activity (TKa) as independent predictor of outcome in metastatic breast cancer (MBC) patients in theGEICAM/2013-02 PEARL trial: A predictive biomarker for personalized treatment selection between Capecitabine vs ET + Palbociclib in MBC" GEICAM, Spain Treatment for HR+/HER2- metastatic breast cancer (MBC) with early (≤12 months) progression. TKa can predict for personalized treatment selection between Capecitabine vs ET + Palbociclib CT vs a CDK4/6 inhibitor influence TKa response differently, and the direction and magnitude of the TKa response can predict for benefit to a specific original PEARL study analysis showed no outcome differences between Cape vs ET + Palbo in HR+/HER2- MBC pts, however assessment of TKa before and during therapy identified which patients had the highest probability of responding. "Serum Thymidine Kinase Activity (TKa) as a Potential Biomarker in the Sequential Immunotherapy and Targeted Therapy for Metastatic BRAF V600 Mutated Melanoma (SECOMBIT) trial" 30 centers in: Austria, France Greece, Italy, Spain, Sweden, and Switzerland BRAF V600 mutatedmetastatic melanoma TKa can predict patient outcome inBRAF V600 mutated metastatic melanomaPatients with elevated TKa is an evident poor prognosis study to evaluate the role of TKa as a biomarker in a prospective clinical trial in patients with metastatic melanoma. "Thymidine kinase activity as a prognostic and predictive tool in blood samples from primary ovarian cancer patients" University of Duisburg-Essen, Germany Ovarian Cancer Baseline TKa levels in both serum and plasma significantly correlated with OS and DFS, which identifies circulating TKa as a promising prognostic marker in OC. It might further serve as a predictive marker for response to platinum-based chemotherapy. However, prospective validation of these results is needed in order to further specify the clinical value of TKa. List of abbreviationsBC Breast CancerBL Base Line - prior to treatmentBRAF V600 BRAF is a human gene responsible for producing the protein B-Raf, which is involved in signaling direct cell growth. The V600E mutation describes an amino acid substitution at position 600 in BRAF from a valine (V) to a glutamic acid (E)CDK4/6i CDK4/6 inhibitor treatmentsDFS Disease-Free SurvivalHER2 Human Epidermal Growth Factor Receptor 2HR Hormone receptorHR+ Hormone receptor-positiveMBC Metastatic Breast CancerOS Overall SurvivalPts PatientsTKa Thymidine Kinase activity Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments New DiviTum® TKa data to be presented at ASCO in three cancer types SOURCE: Biovica International View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
